A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer Patients
Latest Information Update: 13 Dec 2010
Price :
$35 *
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Dec 2010 New trial record